The Covid-19 pandemic gave big pharma big payday. But it also caused the industry to rethink a globalized supply chain centered on Asia. What will it take to reshore at least some generic drugs to the U.S.
Can the U.S. really bring manufacturing home? A McKinsey study shows that existing concentration of some supply chains will make it hard. Here’s what needs to be done.
U.S. pharmaceutical imports have skyrocketed in the last ten years, with imports from China, India and Mexico leading the surge.
One of India’s pharmaceutical labs has run afoul of the FDA many times this year. The U.S. is dependent on foreign labs like Aurobindo for its drug supply. Can the government help change that?
As 2022 winds down, one thing remains clear, globalization is losing support among policy makers, and even among influencers like Paul Krugman.
The Congressional-Executive Commission on China hears testimony about Zero Covid and the human rights abuses its exacerbated in the world’s No. 2 economy. In a report by the Commission, calls for more capital market sanctions.
Most people think that when a drug is recalled by the lab, it is pulled from pharmacy shelves. It’s not. Here’s how drug recalls really work.
In his recent WSJ column “Strong Dollar Wins the Inflation Battle in New Spin on Currency Wars,” James Mackintosh suggests that the dollar’s sharp appreciation
The FDA Safety and Landmark Advancements (FDASLA) Act has passed a key committee, with 25 out of some 30 amendments passing. Generics and baby formula crisis got most of the attention.
WASHINGTON — The Coalition for a Prosperous America (CPA) today sent a letter to Dr. Robert Califf, Commissioner of the Food and Drug Administration (FDA),
